{"id":29578,"date":"2026-01-07T04:27:00","date_gmt":"2026-01-06T20:27:00","guid":{"rendered":"https:\/\/csccm.org.cn\/?p=29578"},"modified":"2026-01-07T05:52:53","modified_gmt":"2026-01-06T21:52:53","slug":"jama%e5%8f%91%e8%a1%a8%e8%ae%ba%e6%96%87%ef%bc%9a%e5%9f%ba%e4%ba%8e%e8%82%8c%e9%85%90%e5%92%8c%e5%85%89%e6%8a%91%e7%b4%a0c%e8%ae%a1%e7%ae%97%e7%9a%84egfr%e5%b7%ae%e5%bc%82%e5%8f%8a%e4%b8%b4%e5%ba%8a","status":"publish","type":"post","link":"https:\/\/csccm.org.cn\/?p=29578","title":{"rendered":"[JAMA\u53d1\u8868\u8bba\u6587]\uff1a\u57fa\u4e8e\u808c\u9150\u548c\u5149\u6291\u7d20C\u8ba1\u7b97\u7684eGFR\u5dee\u5f02\u53ca\u4e34\u5e8a\u9884\u540e"},"content":{"rendered":"\n<p>Original Investigation&nbsp;<\/p>\n\n\n\n<h1 class=\"wp-block-heading\">Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis<\/h1>\n\n\n\n<h3 class=\"wp-block-heading\">Michelle M.&nbsp;Estrella,&nbsp;Shoshana H.&nbsp;Ballew,&nbsp;Yingying&nbsp;Sang,&nbsp;et al<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">JAMA Published Online:&nbsp;November&nbsp;7,&nbsp;2025<\/h3>\n\n\n\n<h3 class=\"wp-block-heading\">doi: 10.1001\/jama.2025.17578<\/h3>\n\n\n\n<p>Key Points<\/p>\n\n\n\n<p><strong>Question<\/strong>&nbsp;&nbsp;Do individuals with a cystatin C\u2013based estimated glomerular filtration rate (eGFRcys) value at least 30% lower than their creatinine-based estimated glomerular filtration rate (eGFRcr) have higher rates of mortality, cardiovascular events, and kidney failure compared with individuals whose eGFRcys is not at least 30% lower than their eGFRcr?<\/p>\n\n\n\n<p><strong>Findings<\/strong>&nbsp;&nbsp;In this individual participant\u2013level meta-analysis of 821\u202f327 participants from 23 cohorts, an eGFRcys at least 30% lower than eGFRcr was associated with higher mortality, cardiovascular events, and kidney failure with replacement therapy, compared with individuals whose eGFRcys was not at least 30% lower than their eGFRcr.<\/p>\n\n\n\n<p><strong>Meaning<\/strong>&nbsp;&nbsp;An eGFRcys value at least 30% lower than eGFRcr was associated with higher rates of mortality, cardiovascular events, and kidney failure with replacement therapy.<a><\/a><\/p>\n\n\n\n<p>Abstract<\/p>\n\n\n\n<p><strong>Importance<\/strong>&nbsp;&nbsp;Estimated glomerular filtration rates (eGFRs) can differ according to whether creatinine or cystatin C is used for the eGFR calculation, but the prevalence and importance of these differences remain unclear.<\/p>\n\n\n\n<p><strong>Objectives<\/strong>&nbsp;&nbsp;To evaluate the prevalence of a discordance between cystatin C\u2013based eGFR (eGFRcys) and creatinine-based eGFR (eGFRcr), identify characteristics associated with greater discordance, and evaluate associations of discordance with adverse outcomes.<\/p>\n\n\n\n<p><strong>Data Sources<\/strong>&nbsp;&nbsp;Participants in the Chronic Kidney Disease Prognosis Consortium (CKD-PC).<\/p>\n\n\n\n<p><strong>Study Selection<\/strong>&nbsp;&nbsp;Participants with concurrent cystatin C and creatinine measurements and clinical outcome measurement.<\/p>\n\n\n\n<p><strong>Data Extraction and Synthesis<\/strong>&nbsp;&nbsp;Between April 2024 and August 2025, data were synthesized using individual-level meta-analysis.<\/p>\n\n\n\n<p><strong>Main Outcomes and Measures<\/strong>&nbsp;&nbsp;The primary independent measurement was a large negative eGFR difference (eGFRdiff), defined as an eGFRcys that was at least 30% lower than eGFRcr. Secondary (dependent) outcomes included all-cause and cardiovascular mortality, atherosclerotic cardiovascular disease, heart failure, and kidney failure with replacement therapy.<\/p>\n\n\n\n<p><strong>Results<\/strong>\u00a0\u00a0A total of 821\u202f327 individuals from 23 outpatient cohorts (mean [SD] age, 59 [12] years; 48% female; 13.5% with diabetes; 40% with hypertension) and 39\u202f639 individuals from 2 inpatient cohorts (mean [SD] age, 67 [16] years; 31% female; 30% with diabetes; 72% with hypertension) were included. Among outpatient participants, 11% had a large negative eGFRdiff (range, 3%-50%). Among inpatients, 35% had a large negative eGFRdiff. Among outpatient participants, at a mean (SD) follow-up of 11 (4) years, a large negative eGFRdiff, compared with an eGFRdiff between \u221230% and 30%, was associated with higher rates of all-cause mortality (28.4 vs 16.8 per 1000 person-years [PY]; hazard ratio [HR], 1.69 [95% CI, 1.57-1.82]), cardiovascular mortality (6.1 vs 3.8 per 1000 PY; HR, 1.61 [95% CI, 1.48-1.76]), atherosclerotic cardiovascular disease (13.3 vs 9.8 per 1000 PY; HR, 1.35 [95% CI, 1.27-1.44]), heart failure (13.2 vs 8.6 per 1000 PY; HR, 1.54 [95% CI, 1.40-1.68]), and kidney failure with replacement therapy (2.7 vs 2.1 per 1000 PY; HR, 1.29 [95% CI, 1.13-1.47]).<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939742\/joi250078f1_1764017915.53657.png?Expires=1768677036&amp;Signature=mXKvrToKWcQqf9ME2Zv3DpWniLiKyykAradf-lt0RoAihqAvcLIp8ISkcMEQHfVGtnVAfdnaVI-pFM3TcJP1gkRsXojh9JB4DmNEQtgqSdNOzBRTcOZsZbXgX-bFmFOtcpXRdey9W1-xY9yCeuf8mozFBNXxdfYhY2W6QMX1XbHc3Ye6gJ-4eC-TImYRcbyMiCk4SMClfjOpcjSK9YVdUj2jKRfZu8DPH1ghoS4xCtIh1Qbz0A02LT5J6Yy~rEnwpQmuhGPt6E7g4MZhoYLoBqaraMutRFKWWVRIe-Op7jhvNi9VRFozERy~KxgWN~d1rzb13jDB-chCDVA8W77xiw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939742\/joi250078f2_1764017915.57657.png?Expires=1768677036&amp;Signature=iN-IshEgZGz3q3A1yoaWHoMMo70aNdqAmaIG41AcNpMqmsMNbwh4GAmtr~3~VZoNStPMrVaZ2MyyaO-utPFJ~W3a~ZZ6J4fB3ouI~aZueMXeW6JV7UlLpsBoOr4rqutUHzzOx-DKGHtjoXhLG9MBaTE1H8lLj0UqebGqba~GaARuozjaeQ03glngPDENGy7Or5JNFfPYLT2CBbtwjndLcK1jnZ9i1omt-cAyDUQvMYryoPUdvs8WNw9jmNXU6HU5IMzbn7iY-kszmaH6Igu22mFV7ma7ExIrPtbaXbLDHKT~OV3-eU3UaYjE7HXVnjWX3R9HJUxHMnIrSdh~fu3xog__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939742\/joi250078t1_1764017915.50551.png?Expires=1768677036&amp;Signature=sd~jb1PEdlQ4xlRRr8R617WRGc5xSzYaZWzDfcQmF57Yfyz~CAuo3OtGbrjI-XcV5ZgEgOiVHoYK2FSSs~elrOD-pL2mTBS7Q-AzcWKXtCGqpw8w~QqxxMFilv9jiOBoRSLf4pcUspB9g~hAxWYneLXM63tG4QiGcD-1HdEUsI4TfX8osGLKxXN9059bj5ma1rhq0DtStCovHaxIT8IW3q9BXw~Wk68yCj--Tg58a7guwwj5yTJ6yXxId~OKg1e~uR0jFUGRWalxyPTopid0E1p2kC4QtM16MFgpXBcKJDipVeDLXOL~bizAXNHCc9-6~odpu9Afs7DGxX7TM4Icog__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939742\/joi250078t2_1764017915.53156.png?Expires=1768677036&amp;Signature=G~~fKTTazSqXhDig1~E6R4eT3YDS-6ve9NJUpbRs7Mph-v1g~vp4gA9S1KTPNYQSkZs47O7FRXI9sz4YNnMz5LaZxAaqUrBgg4Q35uy3OAi77sg7Zw3Q-aMniNPeioPuKilixCdg8cHKLLlVPINxnqJ82A94dUqP2dax0sF7nd6XXfu4riwC3Ypdgl0b9kPeVx2TEft7XlT1026HgfsBRBARNqmdUEJDZrg1vClWQX3IM5oun56atz13YiJc2bheiv5NlmhsoLpo8hvcnk94WoALllWbBlN8csr0lSsUxHnbxo5fnsZFF77PJIaUhfrDyWSCFopwTUyAownkhqgQoA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939742\/joi250078t3_1764017915.55156.png?Expires=1768677036&amp;Signature=1vSwReIwN62sCmMkF9tWDaMtZTPXHcER9HwJhQ8i1D8kcrHAQzS2gsZ-o6KgOzfLzqsqxI56sKdw9liZBlG4Uk7OE5F2LrQ0nJmupP2ucrbn3Cjvb6y-NXWv00ACuljo3ku9nHMWlPk092Z6h3PvpnWr0utahk~4XJbMq~CMwdwq~RxLQEfMS80UlOJzC9-NsHCDFg~e2KZgkpD44PLceAVfiuWNR6aEfRbCsKhnqs3Blh8pzp7oq0gywxeZnXGosIHhz9JX5Dj7iQTMbSRowUWUjWiKy8tvftewI-evTou~l7kXj3gzcb5GG3lhRmK7AfLOh69jTKBuqKjtrqdViQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939742\/joi250078t4_1764017915.56157.png?Expires=1768677036&amp;Signature=19PNTPe8dTjsrNg-0W6IJg2E-RMHd0em~q3TCzX0jZNvKGW0k6kU6ow74DVjz-PESFULH7Y8BLJjVbYQAwLv7qHRQ045ElAINPO2cJ9UZXXAhJNPImjPF9OUmzyyQx9VAlcYojpdkmc0lofCddxECAP2TT-E0ubOBc4VMkj3Mu355y~mQezFuCbWrFTadTPC6D7hz66PQZVC4~9MK61uTjiqfBNUBk35mO1lzw9yxz40Ws4YkpyzcH03LbKvuH9QJDjhKbkADOreIRGI5-tRuCO~RBmIqDVb~yz1H8K6BwHQUVK5Icwq-L7rfwpE8g2Rqy4botYIy60uOG1itLUzqQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" src=\"https:\/\/cdn.jamanetwork.com\/ama\/content_public\/journal\/jama\/939742\/joi250078t5_1764017915.60157.png?Expires=1768677036&amp;Signature=ZnVpSYlfuAdsodzBeqXRIE~2o0Ed6qCuImH~IXSpThR~QHWQ20yR2-BkngQ5A1fnum2Q0r-vA9pRfPzLtEmbY68wxyEjROhEuGUjwqQkS7nH77dbrRw372QEOs6DPvwdyyUaWjgw-qpvt4CLlbBvWFqW6gbfVK0~nbt913z8jvWUppT2ypTB2ynwzm-ZNcBM5kDgW7xUGQ4p28BHIsTKfB-bGODFRoRzGPb6HKO0YnidVEYRwrBtAYmZtP0IuBPlNM-szt-4pIeF~mVmq~nrxF4WY0KTi935XSv9DkWRgFCq3JDZq6BODCEkfK3oLCabxY2rM18Hd~U8P2LUVJzucA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA\" alt=\"\"\/><\/figure>\n\n\n\n<p><strong>Conclusions and Relevance<\/strong>&nbsp;&nbsp;In the CKD-PC, 11% of outpatient participants and 35% of hospitalized patients had an eGFRcys that was at least 30% lower than their eGFRcr. In the outpatient setting, presence of eGFRcys at least 30% lower than eGFRcr was associated with significantly higher rates of all-cause mortality, cardiovascular events, and kidney failure.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Original Investigation&nbsp; Discordance in Creatinine- [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[32,23],"tags":[],"_links":{"self":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29578"}],"collection":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=29578"}],"version-history":[{"count":2,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29578\/revisions"}],"predecessor-version":[{"id":29853,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=\/wp\/v2\/posts\/29578\/revisions\/29853"}],"wp:attachment":[{"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=29578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=29578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csccm.org.cn\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=29578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}